Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 3

Results For "Dr.-Reddy’s"

61 News Found

Dr. Reddy’s acquires trademark rights of breast cancer drug PRIMCYV from Pfizer
News | January 14, 2023

Dr. Reddy’s acquires trademark rights of breast cancer drug PRIMCYV from Pfizer

Dr. Reddy’s will manufacture the Active Pharmaceutical Ingredient and finished drug at its facilities approved by USFDA


Claim against Dr. Reddy’s Laboratories dismissed over Revlimid in US
News | December 30, 2022

Claim against Dr. Reddy’s Laboratories dismissed over Revlimid in US

All claims against the company in the litigation have now been dismissed.


Briefs: J. B. Chemicals & Pharmaceuticals, Dr. Reddy’s Laboratories and Piramal Enterprises
News | December 26, 2022

Briefs: J. B. Chemicals & Pharmaceuticals, Dr. Reddy’s Laboratories and Piramal Enterprises

J. B. Chemicals & Pharmaceuticals has informed that the acquisition of the Razel franchise from Glenmark Pharmaceuticals Limited has been successfully completed.


WEF recognises Dr. Reddy’s Hyderabad factory as part of its Global Lighthouse Network
Digitisation | October 12, 2022

WEF recognises Dr. Reddy’s Hyderabad factory as part of its Global Lighthouse Network

Dr. Reddy’s largest manufacturing facility in Bachupally, Hyderabad, joins Global Lighthouse Network of the World Economic Forum


Binnopharm acquires two anti-bacterial brands from Dr. Reddy’s
Biotech | February 21, 2022

Binnopharm acquires two anti-bacterial brands from Dr. Reddy’s

Dr. Reddy’s, will focus its resources and capabilities on its key therapy spaces of gastroenterology, pain management, cold and flu, allergy, oncology, neurology, paediatrics and women’s health as the Russia and CIS region continues to be a strong performer for the company


Novartis India enters sales and distribution agreement with Dr. Reddy’s
News | February 12, 2022

Novartis India enters sales and distribution agreement with Dr. Reddy’s

Dr. Reddy’s to promote and distribute select Novartis products including the Voveran range, the Calcium range and Methergine in India


Dr. Reddy’s impresses on sustainability and gender equality again
Sustainability | February 03, 2022

Dr. Reddy’s impresses on sustainability and gender equality again

Dr. Reddy’s included in S&P Global’s Sustainability Yearbook for the 2nd year and Bloomberg Gender-Equality Index for the 5th year in a row


Dr. Reddy’s gets approval for Sputnik V Phase 3 trial
News | January 16, 2021

Dr. Reddy’s gets approval for Sputnik V Phase 3 trial

The phase 3 clinical trial of Sputnik V will be conducted on 1,500 subjects as part of the randomized, double blind, parallel group placebo controlled study in India.


Dr. Reddy’s seeks approval to continue Phase 3 trial
News | January 13, 2021

Dr. Reddy’s seeks approval to continue Phase 3 trial

The Phase 2 study of Sputnik V was conducted on 100 subjects as part of the randomized, double-blind, parallel-group, placebo-controlled study in India.


Wockhardt reports FY26 net profit of Rs 317 crore, Board approves fundraising plan
Biopharma | May 04, 2026

Wockhardt reports FY26 net profit of Rs 317 crore, Board approves fundraising plan

Compared to a net loss of Rs 12 crore in FY25, the pharma major reported a consolidated turnaround in its financial performance